Bristol Myers takes up option on Prothena’s PRX019

29 May 2024
bristol_myers_squibb_shutterstock_large

Dublin, Ireland-headquartered protein specialist Prothena (Nasdaq: PRTA) announced that US pharma major Bristol Myers Squibb (NYSE: BMY) has obtained the exclusive global license for PRX019.

BMS will pay $80 million upfront to Prothena, which will also be eligible to receive development, regulatory, and sales milestone payments of up to $617.5 million. Additionally, Prothena will be eligible for tiered royalties on net sales.

The US Food and Drug Administration (FDA) cleared the investigational new drug (IND) application for PRX019, a potential treatment of neurodegenerative diseases with an undisclosed target, in December 2023. Prothena plans to initiate the Phase I clinical trial for PRX019 by year-end 2024.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology